期刊
AAPS JOURNAL
卷 23, 期 1, 页码 -出版社
SPRINGER
DOI: 10.1208/s12248-020-00532-2
关键词
antiviral drugs; anti-SARS-CoV-2 antibody; antiviral vaccines; ARDS; convalescent plasma therapy; immunotherapy; nanotherapeutics
资金
- National Institutes of Health (NIH) [R01 CA238871, R01 CA209818]
This review provides a summary of the latest approaches to diagnostics and therapy of COVID-19, focusing on conventional treatments including antiviral drugs, vaccines, antibody treatments, convalescent plasma therapy, as well as nanoparticle-based approaches. Extensive research and clinical trials are currently ongoing for these treatments in the fight against COVID-19.
The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made a serious public health threat worldwide with millions of people at risk in a growing number of countries. Though there are no clinically approved antiviral drugs and vaccines for COVID-19, attempts are ongoing for clinical trials of several known antiviral drugs, their combination, as well as development of vaccines in patients with confirmed COVID-19. This review focuses on the latest approaches to diagnostics and therapy of COVID-19. We have summarized recent progress on the conventional therapeutics such as antiviral drugs, vaccines, anti-SARS-CoV-2 antibody treatments, and convalescent plasma therapy which are currently under extensive research and clinical trials for the treatment of COVID-19. The developments of nanoparticle-based therapeutic and diagnostic approaches have been also discussed for COVID-19. We have assessed recent literature data on this topic and made a summary of current development and future perspectives.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据